PMID- 19628956
OWN - NLM
STAT- MEDLINE
DCOM- 20100126
LR  - 20151119
IS  - 1423-0259 (Electronic)
IS  - 0030-3747 (Linking)
VI  - 42
IP  - 3
DP  - 2009
TI  - Type 3 choroidal neovascularization associated with fundus flavimaculatus.
PG  - 152-4
LID - 10.1159/000229030 [doi]
AB  - AIM: To describe a patient with type 3 choroidal neovascularization (CNV) 
      associated with fundus flavimaculatus (FFM), who underwent treatment with 
      intravitreal ranibizumab. METHODS: A 78-year-old woman diagnosed with FFM 
      presented at our department complaining of decreased vision and metamorphopsia in 
      her left eye. Upon a complete ophthalmologic examination, including best 
      corrected visual acuity (BCVA), fundus autofluorescence, fluorescein angiography 
      (FA), indocyanine green angiography (ICGA), and spectral domain optical coherence 
      tomography (SD-OCT), the patient was diagnosed with type 3 CNV associated with 
      FFM, and was submitted to intravitreal ranibizumab injections at monthly 
      intervals. RESULTS: Six months after 3 monthly injections of ranibizumab, the 
      patient's BCVA improved from 20/64 to 20/32. FA and ICGA revealed a type 3 CNV 
      closure, and the SD-OCT scan showed a fibrous scar replacing the type 3 CNV, with 
      resolution of serous retinal detachment. CONCLUSION: This case represents the 
      first demonstration of type 3 CNV associated with FFM. Based on our findings, 
      intravitreal ranibizumab may be considered as a therapeutic option for this rare 
      association.
FAU - Quijano, Claudia
AU  - Quijano C
AD  - Department of Ophthalmology, Universite de Paris XII, Creteil, France.
FAU - Querques, Giuseppe
AU  - Querques G
FAU - Massamba, Nathalie
AU  - Massamba N
FAU - Soubrane, Gisele
AU  - Soubrane G
FAU - Souied, Eric H
AU  - Souied EH
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20090723
PL  - Switzerland
TA  - Ophthalmic Res
JT  - Ophthalmic research
JID - 0267442
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunologic Factors)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Choroidal Neovascularization/drug therapy/*etiology/pathology
MH  - Cicatrix/pathology
MH  - Female
MH  - Fluorescein Angiography
MH  - Fundus Oculi
MH  - Humans
MH  - Immunologic Factors/administration & dosage
MH  - Ranibizumab
MH  - Retinal Degeneration/*complications/pathology
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity/drug effects
EDAT- 2009/07/25 09:00
MHDA- 2010/01/27 06:00
CRDT- 2009/07/25 09:00
PHST- 2009/01/01 00:00 [received]
PHST- 2009/03/03 00:00 [accepted]
PHST- 2009/07/25 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2010/01/27 06:00 [medline]
AID - 000229030 [pii]
AID - 10.1159/000229030 [doi]
PST - ppublish
SO  - Ophthalmic Res. 2009;42(3):152-4. doi: 10.1159/000229030. Epub 2009 Jul 23.